WeCare Pharmacy, a leader in personalized pharmaceutical compounding, is proud to announce the formal development and buildout of its new 34,000-square-foot 503B pharmacy outsourcing facility, scheduled for 2027.
This upcoming expansion marks a pivotal milestone in the company’s history, advancing its ability to provide large-scale solutions for hospitals, clinics, and healthcare systems while maintaining the patient-centric, personalized care approach that has defined the WeCare brand.
The facility will feature a state-of-the-art cleanroom and manufacturing space, along with a range of high-tech equipment and automation, with a footprint designed to scale production safely and efficiently. This strategic expansion is projected to bring up to 150 new high-skilled healthcare, pharmacy, and manufacturing jobs to the local Northern Virginia economy over the next two years.
What This Means for Healthcare Providers
For healthcare providers and hospital systems, this buildout translates directly into enhanced supply chain reliability, helping to mitigate the chronic drug shortages that complicate daily clinical operations. For patients, the scale of a 503B facility means more consistent access right at the point of care, reducing treatment delays.
As the healthcare landscape evolves, the demand for reliable, high-volume access to sterile and non-sterile compounded medications has never been greater. By transitioning toward 503B status, WeCare is positioning itself to meet these needs on a national scale. The upcoming facility is being designed to meet rigorous cGMP standards, helping ensure that every batch produced meets the highest benchmarks for safety, identity, strength, quality, and purity.
A Commitment to Quality and Safety
Safety is the cornerstone of the WeCare mission. This buildout represents an investment in the future of pharmaceutical integrity.
Following the success of their specialized 503A services, which focus on individual patient prescriptions, the 503B pharmacy will utilize advanced automation, cleanroom technology, and exhaustive third-party testing to provide clinicians with the office-use bulk medications they require to operate effectively.
“Our journey has always been driven by the needs of our patients and the providers who care for them. The development of our new 503B pharmacy is the natural evolution of that mission,” said Xuan Huynh, PharmD, founder of WeCare. “The goal is to empower healthcare providers with a dependable supply chain of high-quality compounds, ensuring they never have to choose between scale and clinical excellence.”
Continued Growth and Innovation
This expansion is part of WeCare’s long-term growth strategy to become a full-spectrum pharmaceutical partner. By matching the capabilities of industry leaders while retaining a boutique, high-touch service model, WeCare aims to solve the chronic drug shortages and quality inconsistencies that medical facilities often face. While the 503B facility is currently in the buildout and regulatory preparation phase, WeCare remains fully operational in its 503A capacity, continuing to serve its current provider partners with excellence.
